Physician profile
Moises Garcia Rosa
NPI 1699122739
$2,065.73
in general payments reported to CMS, 2019-2025
13 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2023: $125 · 2024: $401 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $613.02 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $264.53 | 2025 | |
| Amgen INC. | $245.04 | 2024-2025 | Blincyto, Blincyto |
| Alexion Pharmaceuticals, INC. | $180.81 | 2024-2025 | Soliris, Ultomiris, Koselugo |
| Novo Nordisk INC | $147.06 | 2019 | |
| Genentech USA, INC. | $144.33 | 2019-2024 | Hemlibra |
| Pfizer INC. | $121.98 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.89 | 2023 | |
| Pfizer Pharmaceuticals LLC | $99.94 | 2019 | |
| Csl Behring | $60.15 | 2025 | Humate-P, Idelvion |
| Genentech, INC. | $49.07 | 2025 | Hemlibra |
| Novartis Pharmaceuticals Corporation | $23.20 | 2023 | |
| Sobi, INC | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Garcia Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.